ARID1A and female reproductive organ cancer: Table 1 reports a list of concluded clinical trials where ARID1A mutation was considered in outcome evaluations. Since ARID1A deficiency was firstly discovered in gynecological cancers (95); (47, 45), many clinical trials involved uterine/ovarian cancer patients.